Clinical Trial

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-12.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-04-17
Trial Details
NCT Number NCT06552520
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Atopic Dermatitis
Enrollment 500 participants
Start Date 2024-10-08
Primary Completion 2025-09-11 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-20